Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C;Cinética viral durante el primer mes de tratamiento en pacientes con hepatitis crónica C genotipo 1

Revista Espanola de Enfermedades Digestivas

Volumn 101, Issue 10, 2009, Pages 671-679

  Hernandez A ^a   Domper Bardají, Francisco ^a   Leon A ^a   Lorente, R ^a   Lopez B ^a   De La Santa, E ^a   Cabanillas, M ^a   Paton R ^a   Olmedo, J ^a   Galvan M D ^a   Rodriguez E ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

Author keywords

Hepatitis C; Pegylated interferon; Predictive factors; Treatment; Viremia

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION AND FORECASTING; PREDICTOR VARIABLE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIRAL PHENOMENA AND FUNCTIONS; VIREMIA; VIRUS STRAIN; CLASSIFICATION; GENETICS; GENOTYPE; HEPATITIS C VIRUS; MIDDLE AGED; PROSPECTIVE STUDY; TIME; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; TIME FACTORS; VIRAL LOAD; VIREMIA;

EID: 75349100943     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082009001000002     Document Type: Article

References (18)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 55.
2. Di Bisciglie A. Hepatitis C. Lancet 1998; 351: 351-5.
3. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Combination peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
5. Davis G, Wong J, McHutchison J, Manns M, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 3839: 645-52.
6. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005; 43: 425-33.
7. Fried MW, Hadziyannis SJ, Shiffman M, Messinger D, Zeuzem S. Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection. J Hepatol 2008; 48: S5.
8. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 4: 1260-5.
9. Von Wagner M, Huber M, Brg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40kD) and ribavirin fop 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 5-7.
10. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Egl J Med 2005; 352: 2609-17.
11. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsman Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirinin patients with chronic hepatitis C infected with genotype 1 and low pre-treatment viremia. J Hepatol 2006; 44: 97-103.
12. Zeuzem S, Awlotsky JM, Lukasiewicz E, Von Wagner M, Goulies I, Lurie Y, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43: 250-7.
13. Sánchez-Tapias JM, Diago M, Escartín P, Enriquez J, Romero-Gómez M, Bárcena R, et al. Peginterferon alfa-2a (40KD) plus ribavirin for 48 versus 72 weeks in patients with detectable HCV-RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-60.
14. Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al., Proactive Study Group. Epoeitin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40: 1450-8.
15. Afdhal N, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al., Proactive Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective double-blind randomized, controlled study. Gastroenterology 2004; 126: 1302-11.
16. Shiffman M, Di Bisciegle A, Lindsay K, Morishima C, Wright E, Everson G, et al. Peginterferon alfa 2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-23.
17. Poynard T, Schiff E, Terg R, Moreno Otero R, Flamm S, Schmidt W, et al. Sustained viral response is dependent on baseline characteristic in the retreatment of previous alfa interferon/ribavirin no responders: final results from the EPIC program. J Hepatol 2008; 48(Supl. 2): S369.
18. Alberti A, Chemello L, Benbegnu L. Natural history of hepatitis C. J Hepatol 1999; 31(Supl. 1): 17-24.